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Traditionally, the prospective design has been chosen for risk factor analyses of lifestyle and cancer using
mainly estimation by survival analysis methods. With new technologies, epidemiologists can expand
their prospective studies to include functional genomics given either as transcriptomics, mRNA and
microRNA, or epigenetics in blood or other biological materials. The novel functional analyses should
not be assessed using classical survival analyses since the main goal is not risk estimation, but the anal-
ysis of functional genomics as part of the dynamic carcinogenic process over time, i.e., a ‘‘processual’’
approach. In the risk factor model, time to event is analysed as a function of exposure variables known
at start of follow-up (ﬁxed covariates) or changing over the follow-up period (time-dependent covari-
ates). In the processual model, transcriptomics or epigenetics is considered as functions of time and expo-
sures. The success of this novel approach depends on the development of new statistical methods with
the capacity of describing and analysing the time-dependent curves or trajectories for tens of thousands
of genes simultaneously. This approach also focuses on multilevel or integrative analyses introducing
novel statistical methods in epidemiology. The processual approach as part of systems epidemiology
might represent in a near future an alternative to human in vitro studies using human biological material
for understanding the mechanisms and pathways involved in carcinogenesis.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
The dynamics of human carcinogenesis is still remarkably
unknown, even after intensive research on the cancer genome [1]
and through genomewide association studies (GWAS) [2].
Consequently, functional analyses, here deﬁned as transcriptomics
and epigenetics, have been advocated as a future research direction
of systems epidemiology [3]. Some have even proposed to move
studies of carcinogenesis from animals to ‘‘the human model’’
[4]. Thus, the research challenge is to perform human studies
investigating the time-dependent carcinogenic process. This would
imply the use of prospective cohort studies with suitable biological
material for functional analyses [5]. Presently, the prospective
design has primarily been used for risk analyses relating different
exposures to disease outcome through statistical modelling andestimation. Exposures could be either lifestyle information or
genomic information like single nucleotide polymorphisms, but
might equally well be transcriptomic or epigenetic data. This
risk-related research has traditionally been used for inferring cau-
sal relationships [6]. But functional genomics might offer an addi-
tional distinct process-related approach that could be termed
processual. Processual research describes changes over time in
functional genomics related to the carcinogenic process – like for
instance, changes in oncogenes or tumour suppressor genes. The
aim of this article is to delineate the difference between the causal
and the processual approaches and to raise some methodological
questions generated by this latter, novel approach.From risk factor study to functional analysis
Over the last two decades cohort or prospective studies have
been considered as the most valid design for estimating risk of dis-
eases in relation to different exposures or lifestyle factors, as they
allow for better control of both selection and information biases,
particularly, the alleviation of recall bias observed in case-control
studies [7]. Usually, exposure information is assessed only at start
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exposure information.
The need for more extensive and higher cost information in the
genomic era encouraged a case-control design nested within a
cohort, in which the extensive measures are only carried out in
the sample of the cases with controls selected from the cohort
and matched on pre-determined relevant covariates. This design
has often neglected the time of follow-up by using logistic regres-
sion models instead of survival analyses [8]. Clearly, all laboratory
analyses of functional markers (mRNA, microRNA, methylation)
are expensive, whether they are explored by microarray or by deep
sequencing technologies.
The introduction of functional genomics into a prospective
design as markers of risk can be analysed in the same models as
other exposures as proposed in the ‘‘meet-in-the-middle’’
approach [9]. Again, this is a classical risk factor or causal model.
From the causal perspective, a functional marker may be either
an intermediate in the disease process or an exposure marker. This
distinction is not immediately evident, due to lack of knowledge
about the carcinogenic process. If the functional marker is an inter-
mediate in the disease process, then one would assume that the
level would change over time as predicted from current models
of carcinogenesis. For instance, mRNA or microRNA could easily
be considered as markers of the carcinogenic process changing
with time. In such a situation, the analytical approach must be
reversed since what we want to estimate is the timeline before
diagnosis of changes in the functional marker. This leads to a shift
in paradigm. In the processual approach, the primary concern is to
estimate the time dependency of the marker in relation to the time
before cancer diagnosis.
Hypothesis: processual model
Consequently, in processual analyses, transcriptomics or epige-
netics measured at time of inclusion are considered as measure-
ments at different time points before diagnosis, which is
tantamount to a «look backward» in time. This turn of the point
of view with respect to risk factor study is illustrated in Fig. 1.
The left hand side of Fig. 1 displays a classical prospective GWAS
design including genomic data and exposures like use of hormones,
smoking or levels of organic pollutants, all measured at the inclu-
sion in the study; the x-axis represents the time elapsed since the
beginning of the study, and the failure time for a case-control pair
corresponds to the diagnosis of the case. The point of view adopted
is as follows: given the values of some covariates – genomics and
exposures – what is the risk of developing a cancer at some time?
Thus, genomics and exposure variables are considered as risk fac-
tors for cancer, and the relationship may be expressed in terms
of a survival analysis model:
P½TjE;G
T is the failure time, E the exposures and G the genomics
measurements.
The right hand side of Fig. 1 presents a nested case-control
design including transcriptomics and exposures measured at inclu-
sion in the study; the x-axis represents the time to diagnosis, and
for each case-control pair, the time interval between the transcrip-
tomic measurements and diagnosis is displayed.
The analysis of transcriptomics instead of genomics outputs
raises a different question: how are transcriptomics data affected
by the carcinogenic process? Therefore, transcriptomics are anal-
ysed as potential biomarkers of the carcinogenic process and the
statistical quantity of interest is the distribution of the gene expres-
sion GE as a function of the time to diagnosis T and the exposures E:
P½GEjT;EDiscussion
For practical and economic reasons, only a single measurement
at time of inclusion may be available for each individual. In this
case, the main assumption is that the transcriptomemeasurements
collected on distinct individuals at different times before diagnosis
are consequences of the same carcinogenic process. This point of
view is commonly adopted in lab experiments, e.g., when dissec-
tions performed at different time points on different animals are
analysed as a longitudinal study [10]. In an epidemiological con-
text, the individual variability is expected to be much higher due
to the heterogeneity of cancer. This approach thus relies on the
assumption that available information on the outcome allows
stratiﬁcation according to different biological processes, such as
positive or negative node status at time of diagnosis.
Apart from being canonical in prospective nested case-control
studies, a survival analysis model may appear appropriate for ana-
lysing the links between covariates and time to cancer diagnosis.
More precisely, we will discuss the relevance of classical
semi-parametric models with either additive or multiplicative
effects of the covariates, mostly used in the context of GWAS anal-
ysis, where the dimension of the covariate matrix exceeds the sam-
ple size. Estimation of additive effects in a survival analysis model
requires the knowledge of the covariates at any time before diag-
nosis [11]. In the Cox model [12] which represents one of the most
widely used multiplicative model in epidemiology, the instanta-
neous risk of occurrence of disease is modelled as a function of
the covariates known at time of inclusion. Thus, semi-parametric
models with time-varying covariates cannot be estimated from a
prospective design including a unique measure at time of inclu-
sion, unless covariates are assumed to be constant over time.
Consequently, this assumption would not allow us to address
changes in gene expression over time.A novel point of view in the epidemiological context
Whereas survival analysis targets exposures possibly associated
with cancer, the analysis of transcriptomics and epigenetics
requires the inclusion of exposures which may affect gene expres-
sion regardless of their carcinogenic effect, in order to improve
sensitivity by reducing individual variability. In a purely mechanis-
tic approach for pathway analyses, most studies only concern
cases. Information on functional markers is then usually taken
from tissues and sometimes from blood at time of diagnosis.
Collection of exposure information will thus be liable to recall or
information bias. Studies of the cancer genome used for describing
the carcinogenic process [1] are unable to identify mutations or
functional changes related to exposures. Since different exposures
give different phenotypes of cancer, the sensitivity of the analyses
could be reduced. Classical examples are the differences in risk
estimates of several lifestyle factors and different types of hormone
receptor status in breast cancer [13]. On the other hand, controls
are necessary as a reference level for functional markers. Without
a reference, changes in a functional marker upwards could be
either from a low level to normal, or from normal to a high level.
In addition, information from controls enables the adjustment of
confounding effects of gender, age and lifestyle. The removal of
laboratory batch effects in most designs depends on a strict match-
ing through all laboratory procedures. It should be noted that over
time controls may become cases and the case-control pair would
be removed. If this information is not available through updated
register data or clinical information, then one could estimate the
proportion from the cohort based incidence rates.
The introduction of functional genomics into the traditional
cohort study enables mechanistic analyses of pathways in what
Fig. 1. Schematic description of the traditional cohort design for risk estimation (left panel) and the concept of processual analyses within the same framework (right panel).
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depends on mathematical models estimating the changes in the
functional markers over time. In our functional approach, we use
measurements of gene expression at different time points to esti-
mate the unknown time-dependent function of gene expression.
In this situation transcriptomics or epigenetics become markers
of the underlying disease process like carcinogenesis and not
simply markers of biological risk. The consequences for the use
of different statistical methods are not addressed here, but the
methods used in integrative clinical cancer research demonstrate
the wide range of potential statistical models to be used [14].
Several existing models could be used, especially methods devel-
oped for dynamic longitudinal analyses. In risk estimation with
the Cox proportional hazard model, time can be considered as a
nuisance variable. Commonly used estimators of risk, like relative
risk or the proportional hazard, have no time dimension.
Researchers are not usually interested in the time distribution,
although its values affect the distribution of the observations.
A major challenge to the processual approach is the ability to
discriminate between functional changes due to exposures and
the disease speciﬁc changes due to the inherent disease process
[15]. As an example, smoking results in a lot of gene expression sig-
nals in blood, but not all of these are related to carcinogenesis.
A last comment should be on the complexity of processual anal-
yses compared to risk estimation. In GWAS analyses with hundreds
of thousands of single nucleotide polymorphisms, which are all
treated equally in the same statistical model, a major problem is
the false discovery rate [16]. In processual research, using mRNA
with around 20,000 genes we have no knowledge about the
time-dependency of the expression of individual genes and only
fragmental knowledge about the complex regulatory interplay
between mRNA and up to 1000 microRNA, not forgetting the
450,000 methylation sites, as indicated by the current technology.
It emphasises the need for multi-level analyses. It is also unclear to
what extent these different functional levels are related to either
the exposures or the carcinogenic process or both. Epigenetics
could be a marker of chronic exposures while gene expression
could be related to ongoing functional changes, like the direct
effect of oncogenes or tumour suppressor genes.
Summary
Our aim has been to describe the need for a change in mathe-
matical models generated by the novel options for transcriptomic
analyses in prospective studies as part of a processual approach.
The dynamics of carcinogenesis can now be unravelled in a human
observational design, thus adding an independent source of knowl-
edge about pathways.Conﬂict of interest
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